Game Changing Incentives in Drug Development: Leveraging Pediatric Vouchers

Listen in to our 45-minute webinar on how pediatric review vouchers are an opportunity for you to maximize the potential of your pipeline products while helping pediatric patients with rare diseases. These vouchers offer an opportunity to earn an expedited review voucher worth more than $250 million for development of a product for pediatric patients with rare diseases. Whether you work for a small pharmaceutical company or a large pharmaceutical company, this program can help you maximize the potential of your molecule while driving forward drug development for pediatric patients with rare diseases. You will learn:
  • The history of pediatric review vouchers, and lessons learned from companies seeking approval through this pathway
  • How studying medications in patients with rare diseases can maximize the potential of your pipeline products
  • Strategies for calculating the potential impact of pursuing a rare disease indications; and why this strategy should be pursued for every product.
Copyright HRA Data Driven Intelligence 1974-2019 HRA Data Driven Intelligence, LLC. All rights Reserved.
^